3.4 News

October 14, 2020

Tempus Enters Infectious Disease Market With Large-Scale COVID-19 Testing, Data Initiative

Precision medicine company Tempus has been expanding its data-driven approach to diagnostics even further over the past few months by entering the infectious disease market, starting with COVID-19. In May, the Chicago-based company, which has grown to 1,600 employees, announced that it was launching a diagnostic COVID-19 PCR test at...

September 16, 2020

Tempus and LabCorp Announce Collaboration to Accelerate Clinical Trial Patient Participation

Tempus, a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare, and LabCorp (NYSE: LH), a leading global life sciences company, today announced a collaboration with LabCorp’s drug development business, Covance. LabCorp will participate in Tempus’s TIME Trial® Network and the comp...

July 9, 2020

Fortune Brainstorm Health Conference 2020 | Disease Agnostic: Using AI to Pivot and Combat COVID-19

Eric Lefkofsky and Dr. David Agus discuss Tempus’ pivot to support the fight against COVID-19. Video linked here.    

June 22, 2020

Tempus Announces Christopher Mason, PhD, Joins as Vice President of Emerging Genome Technology

Tempus, a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare, today announced that Christopher Mason, PhD, has joined as the Vice President of Emerging Genome Technology. Dr. Mason has been a pioneer in next-generation sequencing (NGS) diagnostics, multi-omic approaches to modeling disease,...

June 17, 2020

CNBC Disruptor 50 | Tempus: Health Start-Up Backed by Groupon Co-Founder Joins the Fight Against Covid-19

CNBC | Daniel Bukszpan Tempus, a Chicago-based technology company that offers genetic testing and aggregates clinical information, initially focused on cancer patients. But with the coronavirus pandemic spreading across the world, it’s joining the fight against Covid-19. Tempus was founded in 2015 by its CEO, Eric Lefkofsky, who previously co-founded the e-commerce company Groupon in 2008. But while Tempus...

June 1, 2020

Tempus Launches Prospective “Priority” Research Study and Increases Support for Oncology Research Initiatives Despite Pandemic Challenges

Tempus, a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare, today announces its study, along with a collaborative research initiative to expedite project needs during the COVID-19 pandemic. Many oncology research projects have been delayed as building the necessary datasets are difficult...

May 31, 2020

Tempus Launches New Precision Medicine-Driven Tests: Tempus|HRD and Tempus|TO

Tempus, a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare, announced the launch of two new oncology tests designed to equip physicians with even more precise genomic data in an effort to improve therapeutic outcomes. Tempus|HRD, a test that identifies a...

May 30, 2020

Tempus Launches COVID-19-Specific Clinical and Research Initiatives for Oncology

Tempus, a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare, introduced a series of offerings designed to both advance vital research and support physicians in treating cancer patients, despite the challenges of the COVID-19 pandemic. Tempus is equipping physicians with the tools...

May 29, 2020

Tempus TIME Trial™ Program Reaches Critical Scale and Operational Milestones

Tempus, a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare, has reached a milestone in fully enrolling 2,500 oncologists into its Tempus Integrated Molecular Evaluation (TIME) Trial™ Program that seeks to rapidly match patients largely in the community setting to targeted clinical trials....

May 15, 2020

Tempus Announces Expansion Into Infectious Diseases, Starting with COVID-19

Tempus, a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare, today announced its expansion into infectious diseases, starting with COVID-19. Tempus is leveraging its existing capabilities to launch a diagnostic polymerase chain reaction (PCR) test, as well as a broad-based, healthcare operations...

Show More